Fail-Fast in Respiratory Syncytial Virus Vaccine Development.
作者信息
Besteman Sjanna B, Bont Louis J
机构信息
1Wilhelmina's Children's HospitalUniversity Medical Center UtrechtUtrecht, the Netherlands.
出版信息
Am J Respir Crit Care Med. 2019 Aug 15;200(4):410-412. doi: 10.1164/rccm.201901-0233ED.
Abstract
摘要
相似文献
1
Fail-Fast in Respiratory Syncytial Virus Vaccine Development.
Am J Respir Crit Care Med. 2019 Aug 15;200(4):410-412. doi: 10.1164/rccm.201901-0233ED.
2
Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children.
J Infect Dis. 2020 Feb 3;221(4):534-543. doi: 10.1093/infdis/jiz603.
3
The continuing need for therapeutic agents for respiratory syncytial virus infection.
Antivir Chem Chemother. 2023 Jan-Dec;31:20402066231194424. doi: 10.1177/20402066231194424.
4
So Where Is a Vaccine for Respiratory Syncytial Virus?
Clin Nurse Spec. 2023;37(2):58-60. doi: 10.1097/NUR.0000000000000735.
5
So Where is a Vaccine for Respiratory Syncytial Virus?
Clin Nurse Spec. 2023;37(2):E2. doi: 10.1097/NUR.0000000000000736.
6
Respiratory syncytial virus: reverse genetics and vaccine strategies.
Virology. 2002 May 10;296(2):204-11. doi: 10.1006/viro.2002.1437.
7
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
J Infect Dis. 2017 Dec 12;216(11):1362-1370. doi: 10.1093/infdis/jix503.
8
[Prevention of respiratory syncytial virus bronchiolitis].
Arch Pediatr. 2006 Dec;13 Suppl 5:S12-7. doi: 10.1016/s0929-693x(06)80011-4.
9
Respiratory syncytial virus Prefusion F vaccine.
Cell. 2023 Jul 20;186(15):3137-3137.e1. doi: 10.1016/j.cell.2023.05.048.
10
Vaccines Against Respiratory Syncytial Virus: The Time Has Come.
J Infect Dis. 2017 Jan 1;215(1):4-7. doi: 10.1093/infdis/jiw455. Epub 2016 Sep 29.
引用本文的文献
1
Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines.
Pharmaceutics. 2021 Feb 9;13(2):240. doi: 10.3390/pharmaceutics13020240.
2
Automation in the Life Science Research Laboratory.
Front Bioeng Biotechnol. 2020 Nov 13;8:571777. doi: 10.3389/fbioe.2020.571777. eCollection 2020.
3
SARS-CoV-2 infections in cancer outpatients-Most infected patients are asymptomatic carriers without impact on chemotherapy.
Cancer Med. 2020 Nov;9(21):8020-8028. doi: 10.1002/cam4.3435. Epub 2020 Oct 6.
4
Opinions on the current pandemic of COVID-19: Use functional food to boost our immune functions.
J Infect Public Health. 2020 Dec;13(12):1811-1817. doi: 10.1016/j.jiph.2020.08.014. Epub 2020 Sep 10.
本文引用的文献
1
Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
Am J Respir Crit Care Med. 2019 Aug 15;200(4):481-492. doi: 10.1164/rccm.201810-1921OC.
2
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.
Lancet Infect Dis. 2018 Oct;18(10):e295-e311. doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18.
3
Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.
J Infect Dis. 2017 Dec 12;216(11):1398-1406. doi: 10.1093/infdis/jix489.
4
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
N Engl J Med. 2015 Nov 19;373(21):2048-58. doi: 10.1056/NEJMoa1413275.
5
Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.
Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9. doi: 10.1164/rccm.201412-2256OC.
6
Oral GS-5806 activity in a respiratory syncytial virus challenge study.
N Engl J Med. 2014 Aug 21;371(8):711-22. doi: 10.1056/NEJMoa1401184.
7
A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
PLoS One. 2013 Aug 12;8(8):e71072. doi: 10.1371/journal.pone.0071072. eCollection 2013.
8
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.
Am J Epidemiol. 1969 Apr;89(4):422-34. doi: 10.1093/oxfordjournals.aje.a120955.
Zotero 插件